NAS:GWPH (UK) Also Trade In: Germany UK

GW Pharmaceuticals PLC $ 141.70 3.28 (2.37%)

Volume:
277,428
Avg Vol (1m):
353,306
Market Cap $:
4.04 Bil
Enterprise Value $:
3.60 Bil
P/E (TTM):
0.00
P/B:
5.51
Warning! GuruFocus has detected 4 Severe warning signs with GWPH. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

GW Pharmaceuticals PLC News and Headlines -

GuruFocus Articles Total 13
  • 1

Tandem Diabetes Care tops the list

According to the GuruFocus All-In-One Screener as of Monday, the following health care stocks are popular among gurus.

Tandem Diabetes Care Inc. (TNDM) is held by four gurus

The company, which provides products for people with insulin-dependent diabetes, has a market cap of $3.59 billion. Its revenue of $330.11 million has fallen 37.60% over a 10-year period.

6cd75d8edfe349391d09dc3d2b14f883.png

The stock is trading with a price-book ratio of 20.7. The share price of $58 is 18.78% below the 52-week high and 106.46% above the 52-week low. Over the past 10 years, it has lost 68.45%.

214 Views    Tiziano Frateschi    2019-12-16 20:55
Three stocks that will benefit from legalization

Whether you like or not, marijuana represents a growing opportunity for investors. Last year, the legal cannabis market grew by 17% to $5.4 billion. This year, growth estimates have expanded to 25% to reach $6.7 billion.

So far, four U.S. states and the District of Columbia have legalized the recreational use of cannabis. This is in addition to the 24 states that permit medical marijuana. Nine more states will vote on legalization this November (North Dakota was not able to garner enough signatures for the issue to be put on the ballot).

According to Bank

823 Views    Ryan Vanzo    2016-09-17 23:18
Established companies may get into marijuana market by buying developers

Second of two articles

Medical marijuana generated more than $4.2 billion in revenue in the U.S. in 2015, according to ArcView Market Research. And they forecast it will surpass $22 billion by 2020, as regulations continue to loosen and patient access increases.

So why is GW Pharmaceuticals Plc (NASDAQ: GWPH), the largest pharma company with a relatively modest market capitalization of $2 billion, developing marijuana-based drugs? Where are Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Merck (NYSE: MRK), Sanofi (NYSE: SNY) and the rest of their Big Pharma

4336 Views    Barry Cohen    2016-06-13 14:58
Companies striving to bring drugs using cannabis to market face a number of hurdles

First of a two-part series

“I Want to Take You Higher.”

Pharmaceutical companies developing cannabis-based drugs just might be serenading investors with this 1969 hit single by the group Sly and the Family Stone.

But a word of caution to those banking on marijuana drugs to be the blockbusters that send share prices zooming. You could see your investment “go to pot.”

That’s because a lot of heavy lifting still needs to be done before marijuana proves its medical mettle. Look no further than in an editorial titled “Medical Marijuana: Is the Cart Before the Horse?”, which appeared in the

405 Views    Barry Cohen    2016-06-06 03:16
Veritas takes a unique approach to the medicinal marijuana space with its innovative R&D strategy

To date, 39 U.S. states have legalized cannabis for medical use. Total industry revenues during 2015 came in at $4.4 billion. A March report from financial advisory firm Ackrell Capital suggests prohibition will lift entirely by the end of this decade, and the medical marijuana space will be worth an annual $50 billion within 10 years.

This is not a standalone expectation.

Also in March, the Marijuana Business Daily forecasted a high end of $44 billion in economic impact from the cannabis industry by 2020, accounting for both recreational and medicinal consumption.

For the first time in the

1888 Views    George Ronan    2016-04-21 21:30
Largest divestiture is sale of stake in Impax Laboratories

Kyle Bass (Trades, Portfolio) of Hayman Capital Management sold 11 health care-oriented stakes in the fourth quarter, the most noteworthy being the divestiture of his 606,618-share stake in Impax Laboratories Inc. (IPXL), a Hayward, California-based pharmaceutical company.

Bass sold the stake for an average price of $40.13 per share. The transaction had a -9.86% impact on Bass’ portfolio.

Alan Fournier (Trades, Portfolio) is Impax Laboratories’ leading shareholder among the gurus with 2,321,581 shares in his portfolio. The stake is 3.2% of Impax Laboratories’ outstanding shares and 2.53% of Fournier’s total assets.

Impax Laboratories has

1861 Views    David Goodloe    2016-03-01 22:33
Guru also active in energy, agricultural companies

Health care stocks are the most heavily weighted stocks in [url=http://www.gurufocus.com/StockBuy.php?GuruName=Kyle+Bass]Kyle Bass[/url] ([url=http://www.gurufocus.com/StockBuy.php?GuruName=Kyle+Bass]Trades[/url], [url=http://www.gurufocus.com/holdings.php?GuruName=Kyle+Bass]Portfolio[/url])’ portfolio so it is no surprise that health care-related stocks would hold prominent positions in his third-quarter transactions.

Bass’ most significant third-quarter transaction was the sale of his 836,593-share stake in Perrigo Co. PLC (PRGO), a pharmaceutical company with offices in Dublin and Allegan, Mich., for an average price of $183.44 per share. The deal had a -18.25% impact on Bass’ portfolio.

Perrigo has a market cap of $22.03 billion and an enterprise value of $26.88 billion. It has a P/E of 151.2, a forward P/E

1301 Views    David Goodloe    2015-11-27 21:10
Guru purchases 1.28 million shares in CF Industries Holdings, Impax Laboratories and GW Pharmaceuticals

Guru Kyle Bass (Trades, Portfolio) is a great investor, and I really like his investment philosophies. Most recently I read the book "Money" by Anthony Robbins, in which he interviewed Bass. He asked him, "What’s most important to winning?" and Bass replied, “Hunger and pain. Hunger comes from pain; you don’t get really hungry when it’s been easy." He then went on to say, “Luck is where preparation meets opportunity.”

Recently Bass bought 1,281,434 shares in CF Industries Holdings Inc. (CF), Impax Laboratories Inc. (IPXL) and GW Pharmaceuticals (GWPH).

1331627629.png

1072 Views    Kyle Ferguson    2015-11-27 00:22

https://s3.amazonaws.com/gurufocus_userupload/03May20171122131493828533.jpgGW Pharmaceuticals PLC (GWPH)

Shares of GW Pharmaceuticals PLC (GWPH) touched an all-time high of $122.82 during Friday's trading session as the company said that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cannabidiol for the treatment of newborn children with neonatal hypoxic-ischemic encephalopathy, an acute or sub-acute brain injury due to asphyxia caused during the birth process and resulting from deprivation of oxygen during birth (hypoxia).

According to GWPH, it has held a pre-IND meeting with the FDA and expects to submit an Investigational New Drug Application in mid-2015 and to

2255 Views    riddock57    2015-04-24 22:10

By Sarah Roden

The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology companies will be making presentations highlighting drug breakthroughs and updates. Analysts at Cowen & Co., led by Ritu Baral, highlighted what to watch for when several companies present at the annual meeting.

Biogen Inc (BIIB)

Cowen expects Biogen’s presentation at the AAN meeting to garner the highest level of investor focus. Baral expects Biogen to provide incremental data on aducanumab (BIIB037), a drug intended to treat Alzheimer’s disease. BIIB037 slows the growth

1250 Views    TipRanks    2015-04-22 20:36

https://s3.amazonaws.com/gurufocus_userupload/03May20171202191493830939.jpgInter Parfums Inc. (IPAR)

Keep a close eye on IPAR. The company reported strong growth in sales, and said that when it announces its 2014 fourth quarter and full year results in March, IPAR expects to revise the range for its 2015 net income per share guidance upward from its previous guidance of $0.95-$0.98.

For the fourth quarter 2014, IPAR posted consolidated net sales of $125.1 million, an 18.6% increase year over year, and above the above Capital IQ consensus estimate of $120.98 million

https://s3.amazonaws.com/gurufocus_userupload/03May20171202201493830940.png

IPAR creates, produces, and distributes women's fragrances under different

464 Views    riddock57    2015-01-27 21:17

GW Pharmaceuticals (NASDAQ: GWPH) is a British bio-pharmaceutical company best known for its cannabis-based multiple sclerosis treatment, Sativex.

GW Pharmaceuticals in the news

GW Pharmaceuticals is scheduled to announce its fiscal third-quarter earnings report on Tuesday, November 18. Analysts are expecting the company to post a loss of $-0.46 per share for the quarter. During the same quarter last year, the company posted a loss of $-0.29 per share, representing a 58.6% decrease on a year-over-year basis.

The stock currently has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well. Estimates of

792 Views    TipRanks    2014-11-17 17:40

The legal sale of marijuana in Washington State is going to bring a second wave of marijuana stock hype. The issue is that many of these companies are trading OTC where there are less filing requirements and accurate information can be difficult to find. Whenever there is a hyped-up product, there will magically be a surge in companies that have names similar to the product. They seem to merely be setup for pump and dumps. The stocks might get halted at some point in time by the SEC, but it is the investor that gets hurt, not the promoters. The

3774 Views    Chris Mydlo    2014-07-14 18:56

Headlines Total 170
  • 1
  • 2

2021-01-12 $ 133.84 (6.73%)
2:55pm
2:45pm
2021-01-11 $ 125.4 (-2.19%)
7:01am
2021-01-05 $ 116.25 (0.9%)
7:01am
2020-12-21 $ 121.42 (2.17%)
11:01am
2020-12-19
6:36am
2020-12-11 $ 120.43 (-3.08%)
1:23pm
2020-12-07 $ 131.94 (-4.04%)
7:01am
2020-12-03 $ 135.72 (-1.11%)
8:15pm
2020-12-01 $ 137.24 (-2.03%)
11:00am
11:00am
2020-11-30 $ 140.08 (7.99%)
7:00am
2020-11-29
8:00am
2020-11-19 $ 119.3 (-1.42%)
6:29pm
2020-11-18 $ 119.3 (-1.42%)
8:16am
9:15pm
2020-11-13 $ 118.8 (0.92%)
12:31pm
11:00am
10:15pm
2020-11-11 $ 118.53 (1.8%)
1:14pm
2020-11-09 $ 117.41 (2.42%)
7:01am
2020-11-06 $ 110.15 (-0.98%)
7:30pm
2020-11-03 $ 108.21 (21.19%)
3:22pm
2:05pm
1:01pm
1:01pm
7:00am
2020-11-02 $ 89.29 (-0.8%)
9:47am
9:43am
7:50am
7:50am
2020-10-30 $ 90.01 (0.76%)
10:15am
2020-10-28 $ 88.82 (-2.13%)
6:00pm
2020-10-27 $ 90.75 (-1.5%)
9:36am
2020-10-26 $ 92.13 (-3.02%)
7:00am
6:56am
6:54am
2020-10-22 $ 97.04 (0.15%)
11:00am
2020-10-21 $ 96.89 (0.56%)
11:00am
2020-10-20 $ 96.35 (0.29%)
5:52am
2020-09-27
6:36am
2020-09-23 $ 100 (-0.99%)
8:00am
3:00am
2020-09-16 $ 107.13 (0.22%)
7:52pm
2020-09-11 $ 100.02 (-2.91%)
7:01pm
7:01pm
2020-09-10 $ 100.02 (-2.91%)
7:08am
7:00am
2020-09-03 $ 102.43 (0.57%)
6:30am
2020-09-01 $ 100.88 (-2.95%)
7:00am
2020-08-29
6:41am
2020-08-26 $ 104.24 (0.96%)
11:30am
2020-08-24 $ 106.27 (-2.78%)
7:21am
2020-08-16
10:47am
2020-08-09
6:45am
2020-08-08
7:45am
7:34pm
2020-08-07 $ 132.1 (-2.1%)
7:58pm
2020-08-06 $ 132.1 (-2.1%)
9:14am
2020-08-05 $ 134.94 (-0.32%)
8:42am
2020-08-04 $ 135.37 (1.88%)
7:50am
6:37am
6:35am
6:32am
6:30am
2020-08-03 $ 132.87 (4.11%)
3:45pm
3:36pm
7:56am
7:54am
7:45am
7:00am
2020-08-02
9:34am
2020-07-30 $ 129.7 (2.36%)
10:53am
5:36am
2020-07-26
8:10am
2020-07-25
6:56am
2020-07-23 $ 129 (-3.69%)
7:00am
2020-07-17 $ 137.13 (1.29%)
4:21pm
2020-07-14 $ 139.54 (5.56%)
8:08am
2020-07-13 $ 132.19 (3.35%)
9:40am
7:21am
2020-07-12
9:34am
2020-07-11
7:48am
6:36am
2020-07-09 $ 128.11 (-0.69%)
6:49am
2020-07-07 $ 129.62 (2.44%)
7:21am
2020-07-01 $ 126.19 (2.83%)
3:55pm
8:36am
2020-06-30 $ 122.72 (0.66%)
8:08am
7:00am
2020-06-29 $ 121.92 (1.43%)
12:00pm
2020-06-28
2:36pm
2020-06-26 $ 120.2 (-3.86%)
9:48am
2020-06-25 $ 125.02 (2.74%)
10:26am
2020-06-24 $ 121.68 (-2.66%)
10:38am
7:00pm
2020-06-20
5:57am
2020-06-18 $ 131.18 (4.36%)
1:57pm
11:47am
10:19am
Total 170
  • 1
  • 2